Sorrento Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Glasgow United Kingdom (1999)

Organization Overview

First Clinical Trial
2008
NCT00804154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sorrento Therapeutics | Sorrento Therapeutics, Inc. | Virttu Biologics Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Amyloidosis (Phase 1)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Ascites (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Cancer Pain (Phase 3)

Carcinoma (Phase 1)

Immunoglobulin Light-chain Amyloidosis (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 1)

Mycoses (Phase 1)

Mycosis Fungoides (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain, Intractable (Phase 3)

Pancreatic Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 73
  • # of Trial APIs: 39